Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierWe are a late-stage clinical biopharmaceutical company focused on developing and commercializing cretostimogene grenadenorepvec (cretostimogene), an investigational oncolytic immunotherapy with a dual mechanism of action designed both to eliminate cancer cells directly by selective replication and indirectly by activating an anti-tumor immune response, as a potential backbone therapy in a broad range of patients afflicted with bladder cancer.
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Business segments
Q1 2026 · $1.1MThe company’s own SEC segment disclosure.
- Commercial And Development$1.1M99%
- License And Collaboration$14.0K1%
CG Oncology, Inc. (CGON) reported revenue of $1.2M in Q2 2026 (quarter ended June 30, 2026). That came with net loss of $79M. For the full year FY2025, revenue was $4.0M (+255% year on year) and net income −$161M. Its largest product in 2026-Q1 was Commercial And Development at $1.1M, 99% of the disclosed total, just ahead of License And Collaboration at 1.3%.
Raw charts
9 series · TTMAs reported to the SEC, without any scoring.